Myriad Genetics Inc
MYGN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$23.20 | Kpxq | Tywzcwtss |
Myriad Genetics Reports Strong Fourth-Quarter Results; Maintaining $18.50 Fair Value Estimate
Myriad Genetics reported a strong fourth quarter, growing revenue 11% year over year, with solid full-year results slightly higher than our 2022 projections. Quarterly results were driven by hereditary cancer and pharmacogenomics volume growth of 16% and 23%, respectively, while Myriad saw reported revenue decline of 2% for the full year. We maintain our fair value estimate of $18.50, and shares appear fairly valued.